Table 3.

Overview of economic assumptions considered to build the model, resulting from the integration of data from IQVIA^® databases and qualitative interviews with clinicians and former payers

Category	Assumptions
Renegotiations of already marketed drugs	• In the absence of an extension of indication, a 5% additional discount will be applied on top of the discount obtained at previous negotiation • With extension of indication, an 8% additional discount will be applied on top of the one obtained at previous negotiation • Renegotiations are assumed to happen every 3 years • No renegotiation for drugs that have not been renegotiated in the last 5 years
Tender discounts of generics/biosimilars	• Branded small molecules: application of a maximum discount of 70% vs. ex-factory price, reached 2 years after LoE • Generics: application of a maximum discount of 89% vs. originator ex-factory price, reached one year after LoE • Biologics: application of a maximum discount of 41% vs. ex-factory price, reached 3 years after LoE • Biosimilars: application of a maximum discount of 72% vs. originator ex-factory price, reached 3 years after LoE
Negotiation of new launches	• Ublituximab: same cost of therapy per year as 2L treatments weighted average at launch • Tolebrutinib RMS and tolebrutinib PMS: same cost of therapy per year as 2L treatments weighted average at launch • Evobrutinib: same cost of therapy per year as 2L treatments weighted average at launch

LoE loss of exclusivity; PMS progressive multiple sclerosis; RMS  relapsing multiple sclerosis